US Large-Cap Pharma: ASCO 2026 Preview

Research evidence excerpt

US Large-Cap Pharma: ASCO 2026 Preview

in R/R SCLC (oral session), plus additional Phase 1 data in high-grade CNS tumors (poster).

SEZanne Phase 2 trial evaluating ABBV-706 + atezolizumab vs. SOC in previously untreated

extensive-stage SCLC.

○ABBV-969: Clinical debut with initial human safety, PK, and efficacy data in metastatic

castration-resistant prostate cancer.

• Our View The allocation of high-visibility presentation formats (oral abstract session

for ABBV-706, multiple rapid orals for Teliso-A and ABBV-969) indicates potentially

practice-changing or pipeline-validating results. Teliso-V's five abstracts underscore AbbVie's

commitment to broad multi-tumor development of c-Met ADCs. ABBV-706's oral session in

SCLC could represent a significant proof-of-concept moment for the asset and shape future

combination strategies. ABBV-969's mCRPC data will provide initial read on safety/efficacy in

a competitive but commercially attractive space.

• Key Data to Watch

○Teliso-V: Efficacy signals in platinum-resistant ovarian (ORR, DoR, PFS) and competitive

positioning vs. other ADCs (e.g., mirvetuximab soravtansine in FRα+ patients); safety profile

in combination with osimertinib (watch for overlapping ILD/pneumonitis toxicity).

○ABBV-706: Safety and early efficacy signals in R/R SCLC (ORR, DoR).SCLC is a high

unmet need indication with limited durable response options post-platinum; tolerability in

combination with checkpoint inhibitors (budigalimab, atezolizumab) will determine multi-

line development viability.

○ABBV-969: First-in-human safety, MTD/RP2D establishment, and any early efficacy signals

in mCRP. The competitive landscape includes PARP inhibitors, PSMA-targeted therapies, and

novel androgen receptor inhibitors.

Pfizer: Updates for Sigvotatug vedotin and PF'4404